The reference price system and socioeconomic differences in ... - KCE

68 Reference Price System KCE reports 126
45. Koninklijk besluit tot wijziging van het koninklijk besluit van 21 december 2001 tot vaststelling
van de procedures, termijnen en voorwaarden inzake de tegemoetkoming van de verplichte
verzekering voor geneeskundige verzorging en uitkeringen in de kosten van farmaceutische
specialiteiten, B.S. 25 januari 2010.
46. Wet houdende sociale, budgettaire en andere bepalingen, B.S. 03 januari 2001.
47. Koninklijk besluit tot wijziging van het artikel 73, § 2, van de wet betreffende de verplichte
verzekering voor geneeskundige verzorging en uitkeringen gecoördineerd op 14 juli 1994, B.S.
27 september 2005.
48. Soins de Santé/Geneeskundige verzorging. Prescription en dénomination commune
internationale (DCI) - Indiquer les récipés DCI /Voorschrijven op stofnaam (VOS) – Flaggen
van recipes. Brussels: INAMI/RIZIV; 2006. Available from:
49.
http://www.inami.fgov.be/care/fr/other/pharmacists/generalinformation/circulars/pdf/circulardci.pdf
INAMI-CBIP. Mémento-Pharma. Coût des médicaments: Guide Brussels: INAMI-CBIP; 2008.
50. Akkoord geneesheren - ziekenfondsen 2009-2010, B.S. 19 januari 2009.
51. RIZIV/INAMI Brussel [cited Februari 2010]. Nationaal akkoord NCGZ - evaluatie punt 6.
Available from: http://www.riziv.fgov.be/care/nl/doctors/general-information/agreements/2009-
2010/pdf/point6.pdf
52. SPF Economie/FOD Economie Brussels [cited January 2010]. Médicaments à usage humain/
Geneesmiddelen voor menselijk gebruik. Available from:
53.
http://statbel.fgov.be/fr/entreprises/reglementation_de_marche/Prix_reglementes/Geneesmidde
len/index.jsp
Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services
use and on health status in vulnerable populations: a systematic review of the evidence. Int J
Health Serv. 2004;34(1):101-22.
54. Morgan S, Hanley G, Greyson D. Comparison of tiered formularies and reference pricing
policies: a systematic review. Open Medicine. 2009;3(3):131-9.
55. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based
pricing of nitrates on the use and costs of anti-anginal drugs. Canadian Medical Association
Journal. 2001;165(8):1011-9.
56. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of
reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.[see
comment]. CMAJ. 2002;166(6):737-45.
57. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and
economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Clin Pharmacol Ther. 2003;74(4):388-400.
58. Grootendorst PV, Dolovich LR, Holbrook AM, Levy AR, O'Brien BJ. The Impact of Reference
Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from
British Columbia--Volume II: Technical Report. McMaster University, Social and Economic
Dimensions of an Aging Population Research Papers. p 165 pages. 2002. Available from:
http://socserv2.socsci.mcmaster.ca/~sedap/p/sedap71.pdf
59. Grootendorst PV, Dolovich LR, Holbrook AM, Levy AR, O'Brien BJ. The Impact of Reference
Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from
British Columbia--Volume I: Summary. McMaster University, Social and Economic Dimensions
of an Aging Population Research Papers. p 30 pages. 2002. Available from:
http://socserv2.socsci.mcmaster.ca/~sedap/p/sedap70.pdf
60. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the Minimum Pricing Policy and
introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in
Australia. Pharmacoepidemiol Drug Saf. 2001;10(4):295-300.
61. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of
reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Canadian Medical Association Journal. 2002;166(6):737-45.
62. Narine L, Senathirajah M, Smith T. An Assessment of the Impact of Reference-Based Pricing
Policies on the H2 Antagonist Market in British Columbia, Canada. Journal of Research in
Pharmaceutical Economics. 2001;11(1):63-78.